Remus Pharmaceuticals Ltd. - Research Center
Group () BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 23 | Sep ' 22 | |
|---|---|---|
| Sales | 29.04 | 20.48 |
| Operating profit | 9.27 | 4.81 |
| Interest | 0.10 | 0.03 |
| Gross profit | 10.83 | 5.63 |
| EPS (Rs) | 53.01 | 37.52 |
Half yearly
results in details
| Sep ' 23 | Sep ' 22 | |
|---|---|---|
| Other income | 1.66 | 0.85 |
| Stock adjustment | -0.85 | 1.08 |
| Raw material | - | - |
| Power and fuel | - | - |
| Employee expenses | 3.29 | 1.91 |
| Excise | - | - |
| Admin and selling expenses | - | - |
| Research and development expenses | - | - |
| Expenses capitalised | - | - |
| Other expenses | 17.33 | 12.67 |
| Provisions made | - | - |
| Depreciation | 0.42 | 0.09 |
| Taxation | 2.60 | 1.47 |
| Net profit / loss | 7.81 | 4.07 |
| Extra ordinary item | - | - |
| Prior year adjustments | - | - |
| Equity capital | 1.47 | 1.09 |
| Equity dividend rate | - | - |
| Agg.of non-prom. shares (Lacs) | - | - |
| Agg.of non promotoholding (%) | - | - |
| OPM (%) | 31.91 | 23.48 |
| GPM (%) | 35.28 | 26.41 |
| NPM (%) | 25.43 | 19.09 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis